<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02733900</url>
  </required_header>
  <id_info>
    <org_study_id>RC-P0044</org_study_id>
    <nct_id>NCT02733900</nct_id>
  </id_info>
  <brief_title>Modifications of the Subchondral Bone in Aseptic Osteonecrosis of the Femoral Head</brief_title>
  <acronym>ONTF</acronym>
  <official_title>Study of Modifications of the Composition and Structure in the Aseptic Osteonecrosis of the Femoral Head and Etiopathogenic MRI Correlations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lille Catholic University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lille Catholic University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the aim is to identify the modifications responsible for aseptic osteonecrosis
      of the femoral head and its structural evolution by the association of the micro scanner
      analysis and Raman spectrometry performed on the femoral heads removed during hip
      replacements. The study of femoral heads will allow the analysis of bone tissue at two
      different scales, both correlated with the biomechanical properties of the bone. Also, the
      association with preliminary MRI analysis will provide pathogenic explanations correlated to
      these modifications.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Osseous modifications responsible of osteonecrosis</measure>
    <time_frame>through the study completion, an average of 18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total cross-sectional area</measure>
    <time_frame>through the study completion, an average of 27 months</time_frame>
    <description>by using a contrast-enhanced nano-CT for the subchondral plate in necrotic zone, juxta-necrotic zone, remotely of the necrotic zone and cortical of the femoral collar</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cortical bone area</measure>
    <time_frame>through the study completion, an average of 27 months</time_frame>
    <description>by using a contrast-enhanced nano-CT for the subchondral plate in necrotic zone, juxta-necrotic zone, remotely of the necrotic zone and cortical of the femoral collar</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cortical area fraction</measure>
    <time_frame>through the study completion, an average of 27 months</time_frame>
    <description>by using a contrast-enhanced nano-CT for the subchondral plate in necrotic zone, juxta-necrotic zone, remotely of the necrotic zone and cortical of the femoral collar</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cortical thickness</measure>
    <time_frame>through the study completion, an average of 27 months</time_frame>
    <description>by using a contrast-enhanced nano-CT for the subchondral plate in necrotic zone, juxta-necrotic zone, remotely of the necrotic zone and cortical of the femoral collar</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone volume fraction</measure>
    <time_frame>through the study completion, an average of 27 months</time_frame>
    <description>by using a contrast-enhanced nano-CT for the subchondral trabecular bone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>trabecular number</measure>
    <time_frame>through the study completion, an average of 27 months</time_frame>
    <description>by using a contrast-enhanced nano-CT for the subchondral trabecular bone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>trabecular separation</measure>
    <time_frame>through the study completion, an average of 27 months</time_frame>
    <description>by using a nano-CT for the subchondral trabecular bone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>trabecular thickness</measure>
    <time_frame>through the study completion, an average of 27 months</time_frame>
    <description>by using a contrast-enhanced nano-CT for the subchondral trabecular bone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physico-chemical composition of the trabecular subchondral bone</measure>
    <time_frame>through the study completion, an average of 27 months</time_frame>
    <description>mineralisation, carbonation, crystallinity, secondary structure of collagen, maturity of collagen, relative content of proteoglycans. These measures will be done for the trabecular subchondral bone in necrotic zone, juxta-necrotic zone, remotely of the necrotic zone and in the cortical of the femoral collar</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Existence and extent of edema</measure>
    <time_frame>through the study completion, an average of 27 months</time_frame>
    <description>this measure will be done on the T2-weighted sequences with fat suppression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perfusion MRI sequence</measure>
    <time_frame>through the study completion, an average of 27 months</time_frame>
    <description>morphological aspect of the enhancement curve, semi-quantitative parameters (slope, area under the curve, time to peak) and pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medullary fat fraction in T1-weighted DIXON method</measure>
    <time_frame>through the study completion, an average of 27 months</time_frame>
    <description>border of osteosclerosis, identification of a necrotic zone, extent of this zone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of osteocyte and adipocyte viability in hematoxylin-eosin-saffron (HES) staining</measure>
    <time_frame>through the study completion, an average of 27 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and ramifications of sub-chondral microvessels by immuno-labeling with CD21</measure>
    <time_frame>through the study completion, an average of 27 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the number of osteoclasts by TRAP (tartrate acid Phosphatase) staining</measure>
    <time_frame>through the study completion, an average of 27 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mankin score for cartilage degradation by Safranin O staining</measure>
    <time_frame>through the study completion, an average of 27 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Femur Head Necrosis</condition>
  <arm_group>
    <arm_group_label>Osteonecrosis group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with an aseptic osteonecrosis of the femoral head</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with coxarthrosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>femoral head removal</intervention_name>
    <arm_group_label>Osteonecrosis group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for experimental group:

          -  Men

          -  Patients aged from 25 to 70 years

          -  Patient with an aseptic osteonecrosis of the femoral head established by medical
             Imaging (CT-scan, MRI or radiography)

          -  FICAT stage 3 or 4

          -  osteonecrosis etiologies : alcohol, corticosteroid therapy, idiopathic

          -  Surgical indication of hip prosthesis determined

        Inclusion Criteria for control group:

          -  Men

          -  Patients aged from 40 to 70 years

          -  Patient with a primitive coxarthrosis

          -  Surgical indication of hip prosthesis determined

        Exclusion Criteria for the 2 groups:

          -  Other causes of osteonecrosis (coagulopathy, barotrauma, trauma)

          -  Prior fracture of the upper extremity of the femur

          -  Prior cancer and hematological malignancies with bone locations

          -  Prior debilitating bone diseases

          -  Patient refusal to participate in the study

          -  Patient who isn't affiliated to a social security regimen
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tristan Pascart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Group of the Catholic Institute of Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amélie Lansiaux, MD PhD</last_name>
    <phone>0033320225269</phone>
    <email>lansiaux.amelie@ghicl.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mélody Plets</last_name>
    <phone>0033320225733</phone>
    <email>plets.melody@ghicl.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Group of the Catholic Institute of Lille</name>
      <address>
        <city>Lomme</city>
        <zip>59462</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mélody Plets</last_name>
      <phone>0033320225733</phone>
      <email>plets.melody@ghicl.net</email>
    </contact>
    <investigator>
      <last_name>Tristan Pascart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2016</study_first_submitted>
  <study_first_submitted_qc>April 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2016</study_first_posted>
  <last_update_submitted>August 22, 2017</last_update_submitted>
  <last_update_submitted_qc>August 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aseptic osteonecrosis</keyword>
  <keyword>femoral head</keyword>
  <keyword>micro scanner</keyword>
  <keyword>Raman spectrometry</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Osteonecrosis</mesh_term>
    <mesh_term>Femur Head Necrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

